⌘K
Loading ticker…
As of 2026-08-24, Medline Inc. Class A common stock (MDLN) has a 3-month relative strength percentile of 36 within the TickerStance CS+ADRC universe (~5,000 tickers). The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 4.4%, relative volume 0.78×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Not enough history to compute monthly seasonality for MDLN.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY diluted average shares. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
MDLN is held by 21 ETFs as of May 2026. Top owner: VHT at 0.15% weight, $28M notional. Top 3 carry $58M.
Held by 58 ETFs · $1.6B across latest filings · largest weight 5.58% (IPO).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VHTVanguard Health Care ETF | 0.15% | $28M | +0.03 pp |
| SCHXSchwab U.S. Large-Cap ETF | 0.02% | $16M | — |
| CGMM | 0.51% | $14M | −0.17 pp |
| SCHBSchwab U.S. Broad Market ETF | 0.02% | $9M | — |
| VONVVanguard Russell 1000 Value ETF | 0.04% | $8M | +0.04 pp |
| SCHVSchwab U.S. Large-Cap Value ETF | 0.05% | $7M | new |
| ONEQ | 0.06% | $7M | −0.03 pp |
| GSEW | 0.17% | $3M | new |
| VONEVanguard Russell 1000 ETF | 0.02% | $2M | +0.02 pp |
| MFSV | 0.41% | $2M | +0.30 pp |
Showing 10 of 21 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News